CA2428971A1 - Conjugues d'un agent therapeutique et d'un porteur peptidique - Google Patents

Conjugues d'un agent therapeutique et d'un porteur peptidique Download PDF

Info

Publication number
CA2428971A1
CA2428971A1 CA002428971A CA2428971A CA2428971A1 CA 2428971 A1 CA2428971 A1 CA 2428971A1 CA 002428971 A CA002428971 A CA 002428971A CA 2428971 A CA2428971 A CA 2428971A CA 2428971 A1 CA2428971 A1 CA 2428971A1
Authority
CA
Canada
Prior art keywords
polypeptide
composition
active agent
peptide
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002428971A
Other languages
English (en)
Inventor
Thomas Piccariello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2001/043089 external-priority patent/WO2003034980A2/fr
Publication of CA2428971A1 publication Critical patent/CA2428971A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne une composition comprenant un polypeptide et du benzatropine mésylate relié par covalence au polypeptide. La présente invention concerne également un procédé d'administration de benzatropine mésylate à un patient, consistant à administrer au patient une composition comprenant un polypeptide et du benzatropine mésylate relié par covalence au polypeptide. En outre, cette invention concerne un procédé permettant de protéger le benzatropine mésylate contre la dégradation, qui consiste à relier le benzatropine mésylate par covalence à un polypeptide. L'invention concerne également un procédé de régulation de la libération de benzatropine mésylate d'une composition, consistant à relier par covalence le benzatropine mésylate au polypeptide.
CA002428971A 2000-11-14 2001-11-14 Conjugues d'un agent therapeutique et d'un porteur peptidique Abandoned CA2428971A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27462200P 2000-11-14 2000-11-14
US60/274,622 2000-11-14
PCT/US2001/043089 WO2003034980A2 (fr) 2000-11-14 2001-11-14 Nouveau compose pharmaceutique contenant du sulfate d'abacavir et procedes de fabrication et d'utilisation associes

Publications (1)

Publication Number Publication Date
CA2428971A1 true CA2428971A1 (fr) 2003-05-01

Family

ID=23048971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002428971A Abandoned CA2428971A1 (fr) 2000-11-14 2001-11-14 Conjugues d'un agent therapeutique et d'un porteur peptidique

Country Status (2)

Country Link
JP (2) JP2006516948A (fr)
CA (1) CA2428971A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
JP4256932B2 (ja) * 1995-06-07 2009-04-22 ジョエル ケイ． スワデッシュ 抗原プロセシング細胞標的複合体
US5846473A (en) * 1996-01-08 1998-12-08 Gb Electrical, Inc. Removal of injection-molded tie from mold by temporarily retaining core between pawl and abutment surface of tie
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
AU729643B2 (en) * 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
ES2200313T3 (es) * 1997-03-03 2004-03-01 Eisai Co., Ltd. Uso de inhibidores de la colinesterasa para tratar trastornos de la atencion.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
AU773420B2 (en) * 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1169024B1 (fr) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Amidon pregelatinise dans une formulation a liberation regulee
CN1122621C (zh) * 1999-05-13 2003-10-01 科马公司 闭锁螺旋封闭系统

Also Published As

Publication number Publication date
JP2006516948A (ja) 2006-07-13
JP2010189419A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
US6716452B1 (en) Active agent delivery systems and methods for protecting and administering active agents
JP4878732B2 (ja) 規制物質の濫用を防ぐための新規な持続放出製薬化合物
US20020099013A1 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
WO2003101476A1 (fr) Systeme d'administration de substances actives et methodes de protection et d'administration de substances actives
AU2001286599A1 (en) Active agent delivery systems and methods for protecting and administering active agents
HK1221477A1 (zh) 多肽及相关化合物的透皮给药系统
AU2003217676A1 (en) Active agent delivery systems and methods for protecting and administering active agents
EA016911B1 (ru) Полиглутаминовые кислоты, функционализированные катионными и гидрофобными группами, и их применения, в частности терапевтические применения
US8080519B2 (en) Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
WO2002051432A1 (fr) Nouveau compose pharmaceutique, ses procedes de preparation, et son utilisation
CA2428971A1 (fr) Conjugues d'un agent therapeutique et d'un porteur peptidique
EP1357928B1 (fr) Nouveau composé pharmaceutique et procédés de fabrication et d'utilisation de ce composé
EP1401374B1 (fr) Nouveau compose pharmaceutique contenant d'atenolol et procedes de fabrication et d'utilisation associes
JP6851977B2 (ja) マクロライド系免疫抑制剤の高分子誘導体
US8772248B2 (en) Drug delivery system
JP2004523480A (ja) 活性作用物質送達系ならびに活性作用物質の保護および投与方法
EP2080511A2 (fr) Systèmes d'administration de principe actif et procédé pour la protection et l'administration de principes actifs
CA2434831C (fr) Drogues a base de polypeptide
CN1476325B (zh) 活性物质的输送系统和活性物质的保护和施用方法
AU2001298033B2 (en) A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
KR100905628B1 (ko) 활성제 전달 시스템 및 활성제의 보호 및 투여 방법
CN101460496A (zh) 单和二取代的羟考酮化合物和组合物
AU5672094A (en) Permeability enhancers for ionic therapeutic polymers
WO1994012516A9 (fr) Composes favorisant la permeabilite des membranes aux polymeres therapeutiques ioniques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130827